Artificial intelligence (AI) in life sciences has moved beyond experimentation. It’s now transforming the process of evidence synthesis underpinning regulatory strategy, pricing decisions, health technology assessments, portfolio prioritization and market access modelling.
In this article for the Silicon Valleys Journal, Lumanity’s Chief Technology Officer Anthony Guethert explores the vital importance of governance and oversight in AI use in life sciences. As AI becomes more embedded in infrastructure and AI-generated outputs underpin regulatory submissions or pricing negotiations, AI use without formalized, operational governance risks building a house of cards.
